Masafumi Kitakaze

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/75359/publications.pdf

Version: 2024-02-01

136	8,927	47006	42399
papers	citations	47	92
		h-index	g-index

140	140	140	10559
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Antacid Therapy in Coronary Artery Disease and Heart Failure: Proton Pump Inhibitors vs. H2 Receptor Blockers. Cardiovascular Drugs and Therapy, 2024, 38, 181-189.	2.6	5
2	Efficacy and Safety of Early Initiation of Eplerenone Treatment in Patients with Acute Heart Failure (EARLIER trial): a multicentre, randomized, double-blind, placebo-controlled trial. European Heart Journal - Cardiovascular Pharmacotherapy, 2022, 8, 108-117.	3.0	13
3	Daily self-monitoring of blood pressure decreases systolic and diastolic blood pressure in hypertensive participants. Heart and Vessels, 2022, 37, 1265-1270.	1.2	1
4	Is Aspirin Loading Before Primary Percutaneous Coronary Intervention for Patients with ST-Elevation Myocardial Infarction Necessary?. Cardiovascular Drugs and Therapy, 2022, , 1.	2.6	2
5	Antihypertrophic Memory After Regression of Exercise-Induced Physiological Myocardial Hypertrophy Is Mediated by the Long Noncoding RNA Mhrt779. Circulation, 2021, 143, 2277-2292.	1.6	45
6	JCS/JHFS 2018 Guideline on the Diagnosis and Treatment of Cardiomyopathies. Circulation Journal, 2021, 85, 1590-1689.	1.6	45
7	ASB2 is a novel E3 ligase of SMAD9 required for cardiogenesis. Scientific Reports, 2021, 11, 23056.	3.3	5
8	Lansoprazole alleviates pressure overload-induced cardiac hypertrophy and heart failure in mice by blocking the activation of Î²-catenin. Cardiovascular Research, 2020, 116, 101-113.	3.8	32
9	Overexpression of Na+-HCO3â€“ cotransporter contributes to the exacerbation of cardiac remodeling in mice with myocardial infarction by increasing intracellular calcium overload. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2020, 1866, 165623.	3.8	6
10	Arterial stiffening is a crucial factor for left ventricular diastolic dysfunction in a community-based normotensive population. International Journal of Cardiology: Hypertension, 2020, 6, 100038.	2.2	6
11	Plasma indoxyl sulfate levels predict cardiovascular events in patients with mild chronic heart failure. Scientific Reports, 2020, 10, 16528.	3.3	11
12	Artificial Intelligence Uncovered Clinical Factors for Cardiovascular Events in Myocardial Infarction Patients with Glucose Intolerance. Cardiovascular Drugs and Therapy, 2020, 34, 535-545.	2.6	3
13	Plasma BNP Levels and Diuretics Use as Predictors of Cardiovascular Events in Patients with Myocardial Infarction and Impaired Glucose Tolerance. Cardiovascular Drugs and Therapy, 2020, 34, 79-88.	2.6	5
14	Endogenously released adenosine causes pulmonary vasodilation during the acute phase of pulmonary embolization in dogs. IJC Heart and Vasculature, 2019, 24, 100396.	1.1	0
15	AST-120, an Adsorbent of Uremic Toxins, Improves the Pathophysiology of Heart Failure in Conscious Dogs. Cardiovascular Drugs and Therapy, 2019, 33, 277-286.	2.6	11
16	A dipeptidyl peptidase-IV inhibitor improves diastolic dysfunction in Dahl salt-sensitive rats. Journal of Molecular and Cellular Cardiology, 2019, 129, 257-265.	1.9	15
17	Effects of Teneligliptin on the Progressive Left Ventricular Diastolic Dysfunction in Patients with Type 2 Diabetes Mellitus in Open-Label, Marker-Stratified Randomized, Parallel-Group Comparison, Standard Treatment-Controlled Multicenter Trial (TOPLEVEL Study): Rationale and Study Design. Cardiovascular Drugs and Therapy, 2019, 33, 363-370.	2.6	6
18	JCS 2017/JHFS 2017 Guideline on Diagnosis and Treatment of Acute and Chronic Heart Failureã€€â€• Digest Version â€•. Circulation Journal, 2019, 83, 2084-2184.	1.6	446

#	Article	IF	Citations
19	An Exploratory Study of Dapagliflozin for the Attenuation of Albuminuria in Patients with Heart Failure and Type 2 Diabetes Mellitus (DAPPER). Cardiovascular Drugs and Therapy, 2018, 32, 183-190.	2.6	7
20	The impact of creating mathematical formula to predict cardiovascular events in patients with heart failure. Scientific Reports, 2018, 8, 3986.	3.3	7
21	Olmesartan attenuates pressure-overload- or post-infarction-induced cardiac remodeling in mice. Oncotarget, 2018, 9, 24601-24618.	1.8	1
22	Cardiovascular Outcomes in Patients With Previous Myocardial Infarction and Mild Diabetes Mellitus Following Treatment With Pioglitazone. EClinicalMedicine, 2018, 4-5, 10-24.	7.1	9
23	Dysfunction of microtubules induces cardiac dysfunction. EBioMedicine, 2018, 37, 3-4.	6.1	2
24	The Impact of Bronchodilator Therapy on Systolic Heart Failure with Concomitant Mild to Moderate COPD. Diseases (Basel, Switzerland), 2018, 6, 4.	2.5	9
25	Double-Blind, Randomized, Placebo-Controlled Trial Evaluating the Efficacy and Safety of Eplerenone in Japanese Patients With Chronic Heart Failure (J-EMPHASIS-HF). Circulation Journal, 2018, 82, 148-158.	1.6	23
26	Rationale and Design of the Multicenter Trial on Japan Working Group on the Effects of Angiotensin Receptor Blockers Selection (Azilsartan vs. Candesartan) on Diastolic Function in the Patients Suffering from Heart Failure with Preserved Ejection Fraction: J-TASTE Trial. Cardiovascular Drugs and Therapy, 2018, 32, 381-388.	2.6	3
27	Elucidation of the Strongest Predictors of Cardiovascular Events in Patients with Heart Failure. EBioMedicine, 2018, 33, 185-195.	6.1	8
28	Reply to â€˜Use of serum fibroblast growth factor 23 vs. plasma B-type natriuretic peptide levels in assessing the pathophysiology of patients with heart failureâ€™. Hypertension Research, 2017, 40, 900-901.	2.7	0
29	A Pathophysiological Role of Plasma Indoxyl Sulfate in Patients with Heart Failure. International Journal of Gerontology, 2017, 11, 62-66.	0.6	3
30	RNA Aptamer Binds Heparin-Binding Epidermal Growth Factor-Like Growth Factor with High Affinity and Specificity and Neutralizes Its Activity. International Journal of Gerontology, 2017, 11, 191-196.	0.6	0
31	Pathophysiology of cardiorenal syndrome in patients with heart failure: potential therapeutic targets. American Journal of Physiology - Heart and Circulatory Physiology, 2017, 313, H715-H721.	3.2	28
32	Does Treatment of Impaired Glucose Tolerance Improve Cardiovascular Outcomes in Patients with Previous Myocardial Infarction?. Cardiovascular Drugs and Therapy, 2017, 31, 401-411.	2.6	19
33	Novel Synthesized Radical-Containing Nanoparticles Limit Infarct Size Following Ischemia and Reperfusion in Canine Hearts. Cardiovascular Drugs and Therapy, 2017, 31, 501-510.	2.6	22
34	Radiation-induced HFpEF model as a potential tool for the exploration of novel therapeutic targets. American Journal of Physiology - Heart and Circulatory Physiology, 2017, 313, H323-H325.	3.2	1
35	Why publish in the American Journal of Physiology-Heart and Circulatory Physiology?. American Journal of Physiology - Heart and Circulatory Physiology, 2017, 313, H221-H223.	3.2	4
36	Use of serum fibroblast growth factor 23 vs. plasma B-type natriuretic peptide levels in assessing the pathophysiology of patients with heart failure. Hypertension Research, 2017, 40, 181-188.	2.7	13

#	Article	IF	Citations
37	Translational Study of Hydrogen Gas Inhalation as Adjuncts to Reperfusion Therapy for Acute Myocardial Infarction. Circulation Journal, 2017, 81, 936-937.	1.6	6
38	FGF23 promotes myocardial fibrosis in mice through activation of Î²-catenin. Oncotarget, 2016, 7, 64649-64664.	1.8	100
39	Non-linear Equation using Plasma Brain Natriuretic Peptide Levels to Predict Cardiovascular Outcomes in Patients with Heart Failure. Scientific Reports, 2016, 6, 37073.	3.3	9
40	Acute hyperglycemia suppresses left ventricular diastolic function and inhibits autophagic flux in mice under prohypertrophic stimulation. Cardiovascular Diabetology, 2016, 15, 136.	6.8	26
41	Histone Deacetylase Inhibitor Phenylbutyrate Exaggerates Heart Failure in Pressure Overloaded Mice independently of HDAC inhibition. Scientific Reports, 2016, 6, 34036.	3.3	27
42	Clinical Evidence of the Role of Histamine in Heart Failure â^—. Journal of the American College of Cardiology, 2016, 67, 1553-1555.	2.8	10
43	Chemical Endoplasmic Reticulum Chaperone Alleviates Doxorubicin-Induced Cardiac Dysfunction. Circulation Research, 2016, 118, 798-809.	4.5	88
44	Recent Progress and Next Challenges in the Treatment of Symptomatic Heart Failure in Japan. Circulation Journal, 2015, 79, 2322-2323.	1.6	0
45	Targeting lysosomal Ca2+to reduce reperfusion injury. Cardiovascular Research, 2015, 108, 321-323.	3.8	1
46	Impact of Either GLP-1 Agonists or DPP-4 Inhibitors on Pathophysiology of Heart Failure. International Heart Journal, 2015, 56, 372-376.	1.0	10
47	Influence of the Lactotripeptides Isoleucineâ€“Prolineâ€“Proline and Valineâ€“Prolineâ€“Proline on Systolic Blood Pressure in Japanese Subjects: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. PLoS ONE, 2015, 10, e0142235.	2.5	25
48	Azilsartan, but not Candesartan Improves Left Ventricular Diastolic Function in Patients with Hypertension and Heart Failure. International Journal of Gerontology, 2015, 9, 201-205.	0.6	11
49	Rationale and Design of the Double-Blind, Randomized, Placebo-Controlled Multicenter Trial on Efficacy of Early Initiation of Eplerenone Treatment in Patients with Acute Heart Failure (EARLIER). Cardiovascular Drugs and Therapy, 2015, 29, 179-185.	2.6	9
50	An interaction between glucagon-like peptide-1 and adenosine contributes to cardioprotection of a dipeptidyl peptidase 4 inhibitor from myocardial ischemia-reperfusion injury. American Journal of Physiology - Heart and Circulatory Physiology, 2015, 308, H1287-H1297.	3.2	30
51	Myocardial Hypertrophic Preconditioning Attenuates Cardiomyocyte Hypertrophy and Slows Progression to Heart Failure Through Upregulation of S100A8/A9. Circulation, 2015, 131, 1506-1517.	1.6	66
52	Data Mining as a Powerful Tool for Creating Novel Drugs in Cardiovascular Medicine: The Importance of a â€œBack-and-Forth Loopâ€•Between Clinical Data and Basic Research. Cardiovascular Drugs and Therapy, 2015, 29, 309-315.	2.6	6
53	Plasma B-type natriuretic peptide is a useful tool for assessing coronary heart disease risk in a Japanese general population. Hypertension Research, 2015, 38, 74-79.	2.7	10
54	Trends in Characteristics of CVD in AsiaÂand Japan. Journal of the American College of Cardiology, 2015, 66, 196-198.	2.8	9

#	Article	IF	Citations
55	Disruption of histamine H2 receptor slows heart failure progression through reducing myocardial apoptosis and fibrosis. Clinical Science, 2014, 127, 435-448.	4.3	51
56	Pathophysiological impact of serum fibroblast growth factor 23 in patients with nonischemic cardiac disease and early chronic kidney disease. American Journal of Physiology - Heart and Circulatory Physiology, 2014, 307, H1504-H1511.	3.2	42
57	Evaluation of intramitochondrial ATP levels identifies G0/G1 switch gene 2 as a positive regulator of oxidative phosphorylation. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 273-278.	7.1	101
58	Using Basic and Clinical Research in Cardiology to Achieve Personalized Medicine. Journal of the American College of Cardiology, 2014, 64, 946-948.	2.8	2
59	Cytosolic CARP Promotes Angiotensin II- or Pressure Overload-Induced Cardiomyocyte Hypertrophy through Calcineurin Accumulation. PLoS ONE, 2014, 9, e104040.	2.5	16
60	Histamine H2 receptor activation exacerbates myocardial ischemia/reperfusion injury by disturbing mitochondrial and endothelial function. Basic Research in Cardiology, 2013, 108, 342.	5.9	77
61	Derivation of a mathematical expression for predicting the time to cardiac events in patients with heart failure: a retrospective clinical study. Hypertension Research, 2013, 36, 450-456.	2.7	8
62	It is Time to Reconsider the Cardiovascular Protection Afforded by RAAS Blockade - Overview of RAAS Systems. Cardiovascular Drugs and Therapy, 2013, 27, 133-138.	2.6	8
63	Dipeptidyl-peptidase IV inhibition improves pathophysiology of heart failure and increases survival rate in pressure-overloaded mice. American Journal of Physiology - Heart and Circulatory Physiology, 2013, 304, H1361-H1369.	3.2	54
64	Direct comparison of the diagnostic capability of cardiac magnetic resonance and endomyocardial biopsy in patients with heart failure. European Journal of Heart Failure, 2013, 15, 166-175.	7.1	62
65	Urgent Management of Rapid Heart Rate in Patients With Atrial Fibrillation/Flutter and Left Ventricular Dysfunction. Circulation Journal, 2013, 77, 908-916.	1.6	99
66	Impact of Physical Activity on Cardiovascular Events in Patients With Chronic Heart Failure. Circulation Journal, 2013, 77, 2963-2972.	1.6	30
67	Deficiency of type 1 cannabinoid receptors worsens acute heart failure induced by pressure overload in mice. European Heart Journal, 2012, 33, 3124-3133.	2.2	20
68	Serum Blood Urea Nitrogen and Plasma Brain Natriuretic Peptide and Low Diastolic Blood Pressure Predict Cardiovascular Morbidity and Mortality Following Discharge in Acute Decompensated Heart Failure Patients. Circulation Journal, 2012, 76, 2372-2379.	1.6	30
69	Plasma adiponectin levels predict cardiovascular events in the observational Arita Cohort Study in Japan: the importance of the plasma adiponectin levels. Hypertension Research, 2012, 35, 843-848.	2.7	20
70	H2 Mediates Cardioprotection Via Involvements of KATP Channels and Permeability Transition Pores of Mitochondria in Dogs. Cardiovascular Drugs and Therapy, 2012, 26, 217-226.	2.6	45
71	Cardioprotective effects of low-dose combination therapy with a statin and an angiotensin receptor blocker in a rat myocardial infarction model. Journal of Cardiology, 2012, 59, 91-96.	1.9	7
72	Pathophysiology of myocardial reperfusion injury: preconditioning, postconditioning, and translational aspects of protective measures. American Journal of Physiology - Heart and Circulatory Physiology, 2011, 301, H1723-H1741.	3.2	298

#	Article	IF	Citations
73	Detrimental effect of fractalkine on myocardial ischaemia and heart failure. Cardiovascular Research, 2011, 92, 385-393.	3.8	72
74	A histamine H2 receptor blocker ameliorates development of heart failure in dogs independently of Î²-adrenergic receptor blockade. Basic Research in Cardiology, 2010, 105, 787-794.	5.9	38
75	How to Mediate Cardioprotection in Ischemic Heartsâ€"Accumulated Evidence of Basic Research Should Translate to Clinical Medicine. Cardiovascular Drugs and Therapy, 2010, 24, 217-223.	2.6	11
76	Cardioprotection in the Clinical Setting-Lessons from J-WIND Studies. Cardiovascular Drugs and Therapy, 2010, 24, 289-295.	2.6	7
77	AMPK controls the speed of microtubule polymerization and directional cell migration through CLIP-170 phosphorylation. Nature Cell Biology, 2010, 12, 583-590.	10.3	168
78	What Is the Role of ER Stress in the Heart?. Circulation Research, 2010, 107, 15-18.	4.5	26
79	Endoplasmic Reticulum Stress As a Therapeutic Target in Cardiovascular Disease. Circulation Research, 2010, 107, 1071-1082.	4.5	411
80	Ablation of C/EBP Homologous Protein Attenuates Endoplasmic Reticulumâ€"Mediated Apoptosis and Cardiac Dysfunction Induced by Pressure Overload. Circulation, 2010, 122, 361-369.	1.6	231
81	Functional alterations of cardiac proteasomes under physiological and pathological conditions. Cardiovascular Research, 2010, 85, 339-346.	3.8	23
82	Identification of genes related to heart failure using global gene expression profiling of human failing myocardium. Biochemical and Biophysical Research Communications, 2010, 393, 55-60.	2.1	93
83	Antihypertrophic effects of adiponectin on cardiomyocytes are associated with the inhibition of heparin-binding epidermal growth factor signaling. Biochemical and Biophysical Research Communications, 2010, 393, 519-525.	2.1	11
84	Metformin Prevents Progression of Heart Failure in Dogs. Circulation, 2009, 119, 2568-2577.	1.6	269
85	PKA rapidly enhances proteasome assembly and activity in in vivo canine hearts. Journal of Molecular and Cellular Cardiology, 2009, 46, 452-462.	1.9	91
86	Natriuretic Peptides Enhance the Production of Adiponectin in Human Adipocytes and in Patients With Chronic Heart Failure. Journal of the American College of Cardiology, 2009, 53, 2070-2077.	2.8	225
87	Ubiquitin-Proteasome System Impairment Caused by a Missense Cardiac Myosin-binding Protein C Mutation and Associated with Cardiac Dysfunction in Hypertrophic Cardiomyopathy. Journal of Molecular Biology, 2008, 384, 896-907.	4.2	80
88	Overexpression of endoplasmic reticulum-resident chaperone attenuates cardiomyocyte death induced by proteasome inhibition. Cardiovascular Research, 2008, 79, 600-610.	3.8	124
89	Plasma Adiponectin Is Associated with Plasma Brain Natriuretic Peptide and Cardiac Function in Healthy Subjects. Hypertension Research, 2008, 31, 825-831.	2.7	26
90	Atorvastatin Slows the Progression of Cardiac Remodeling in Mice with Pressure Overload and Inhibits Epidermal Growth Factor Receptor Activation. Hypertension Research, 2008, 31, 335-344.	2.7	30

#	Article	IF	Citations
91	Increased Endoplasmic Reticulum Stress in Atherosclerotic Plaques Associated With Acute Coronary Syndrome. Circulation, 2007, 116, 1226-1233.	1.6	335
92	Human atrial natriuretic peptide and nicorandil as adjuncts to reperfusion treatment for acute myocardial infarction (J-WIND): two randomised trials. Lancet, The, 2007, 370, 1483-1493.	13.7	434
93	A cardiac myosin light chain kinase regulates sarcomere assembly in the vertebrate heart. Journal of Clinical Investigation, 2007, 117, 2812-2824.	8.2	140
94	Erythropoietin Enhances Neovascularization of Ischemic Myocardium and Improves Left Ventricular Dysfunction After Myocardial Infarction in Dogs. Journal of the American College of Cardiology, 2006, 48, 176-184.	2.8	123
95	Impact of Blockade of Histamine H2Receptors on Chronic Heart Failure Revealed by Retrospective and Prospective Randomized Studies. Journal of the American College of Cardiology, 2006, 48, 1378-1384.	2.8	91
96	Depression of proteasome activities during the progression of cardiac dysfunction in pressure-overloaded heart of mice. Biochemical and Biophysical Research Communications, 2006, 340, 1125-1133.	2.1	138
97	Blockade ofÂhistamine H2 receptors protects theÂheart againstÂischemia andÂreperfusion injury inÂdogs. Journal of Molecular and Cellular Cardiology, 2006, 40, 666-674.	1.9	28
98	Tiotropium, a Novel Muscarinic M3 Receptor Antagonist, Improved Symptoms of Chronic Obstructive Pulmonary Disease Complicated by Chronic Heart Failure. Circulation Journal, 2006, 70, 1658-1660.	1.6	19
99	Abnormal Glucose Tolerance Contributes to the Progression of Chronic Heart Failure in Patients with Dilated Cardiomyopathy. Hypertension Research, 2006, 29, 775-782.	2.7	24
100	The Antagonism of Aldosterone Receptor Prevents the Development of Hypertensive Heart Failure Induced by Chronic Inhibition of Nitric Oxide Synthesis in Rats. Cardiovascular Drugs and Therapy, 2006, 20, 93-102.	2.6	18
101	Blockade of Angiotensin II Receptors Reduces the Expression of Receptors for Advanced Glycation End Products in Human Endothelial Cells. Arteriosclerosis, Thrombosis, and Vascular Biology, 2006, 26, e138-42.	2.4	32
102	Control of plasma glucose with alpha-glucosidase inhibitor attenuates oxidative stress and slows the progression of heart failure in mice. Cardiovascular Research, 2006, 70, 107-116.	3.8	42
103	Long-Term Stimulation of Adenosine A2b Receptors Begun After Myocardial Infarction Prevents Cardiac Remodeling in Rats. Circulation, 2006, 114, 1923-1932.	1.6	92
104	Exacerbation of heart failure in adiponectin-deficient mice due to impaired regulation of AMPK and glucose metabolism. Cardiovascular Research, 2005, 67, 705-713.	3.8	207
105	Benidipine, a long-acting calcium channel blocker, inhibits cardiac remodeling in pressure-overloaded mice. Cardiovascular Research, 2005, 65, 879-888.	3.8	40
106	Amlodipine ameliorates myocardial hypertrophy by inhibiting EGFR phosphorylation. Biochemical and Biophysical Research Communications, 2005, 327, 1083-1087.	2.1	17
107	A role of opening of mitochondrial ATP-sensitive potassium channels in the infarct size-limiting effect of ischemic preconditioning via activation of protein kinase C in the canine heart. Biochemical and Biophysical Research Communications, 2005, 338, 1460-1466.	2.1	22
108	A calcium channel blocker amlodipine increases coronary blood flow via both adenosine- and NO-dependent mechanisms in ischemic hearts. Journal of Molecular and Cellular Cardiology, 2005, 39, 605-614.	1.9	5

#	Article	IF	Citations
109	Î²-Adrenoceptor Blocker Carvedilol Provides Cardioprotection via an Adenosine-Dependent Mechanism in Ischemic Canine Hearts. Circulation, 2004, 109, 2773-2779.	1.6	48
110	Optimal Windows of Statin Use for Immediate Infarct Limitation. Circulation, 2004, 110, 2143-2149.	1.6	81
111	A Novel Data Mining Approach to the Identification of Effective Drugs or Combinations for Targeted Endpoints?Application to Chronic Heart Failure as a New Form of Evidence-based Medicine. Cardiovascular Drugs and Therapy, 2004, 18, 483-489.	2.6	40
112	Prolonged Endoplasmic Reticulum Stress in Hypertrophic and Failing Heart After Aortic Constriction. Circulation, 2004, 110, 705-712.	1.6	474
113	A calcium channel blocker activates both ecto-5â€²-nucleotidase and NO synthase in HUVEC. Biochemical and Biophysical Research Communications, 2003, 311, 625-628.	2.1	14
114	Activation of Adenosine A 1 Receptor Attenuates Cardiac Hypertrophy and Prevents Heart Failure in Murine Left Ventricular Pressure-Overload Model. Circulation Research, 2003, 93, 759-766.	4.5	120
115	Echocardiographic assessment of LV hypertrophy and function in aortic-banded mice: necropsy validation. American Journal of Physiology - Heart and Circulatory Physiology, 2002, 282, H1703-H1708.	3.2	124
116	Angiotensin-converting enzymeinhibitors and angiotensin iireceptor blockers synergistically increasecoronary blood flow in canine ischemic myocardium. Journal of the American College of Cardiology, 2002, 40, 162-166.	2.8	21
117	Cardiac hypertrophy is inhibited by antagonism of ADAM12 processing of HB-EGF: Metalloproteinase inhibitors as a new therapy. Nature Medicine, 2002, 8, 35-40.	30.7	713
118	Role of Cellular Acidosis in Production of Nitric Oxide in Canine Ischemic Myocardium. Journal of Molecular and Cellular Cardiology, 2001, 33, 1727-1737.	1.9	24
119	Role of mitochondrial and sarcolemmal KATPchannels in ischemic preconditioning of the canine heart. American Journal of Physiology - Heart and Circulatory Physiology, 2001, 280, H256-H263.	3.2	71
120	Role of Phasic Dynamism of p38 Mitogen-Activated Protein Kinase Activation in Ischemic Preconditioning of the Canine Heart. Circulation Research, 2001, 88, 175-180.	4.5	96
121	Differential Subcellular Actions of ACE Inhibitors and AT 1 Receptor Antagonists on Cardiac Remodeling Induced by Chronic Inhibition of NO Synthesis in Rats. Hypertension, 2001, 38, 404-411.	2.7	45
122	Nifedipine-Induced Coronary Vasodilation in Ischemic Hearts Is Attributable to Bradykinin- and NO-Dependent Mechanisms in Dogs. Circulation, 2000, 101, 311-317.	1.6	59
123	Glycoprotein IIb/IIIa Antagonist FK633 Could Not Prevent Neointimal Thickening in Stent Implantation Model of Canine Coronary Artery. Arteriosclerosis, Thrombosis, and Vascular Biology, 1999, 19, 343-347.	2.4	3
124	A Ca channel blocker, benidipine, increases coronary blood flow and attenuates the severity of myocardial ischemia via NO-dependent mechanisms in dogs. Journal of the American College of Cardiology, 1999, 33, 242-249.	2.8	63
125	Adenosine and Cardioprotection in the Diseased Heart. Japanese Circulation Journal, 1999, 63, 231-243.	1.0	60
126	It is the Time to Ask What Adenosine Can Do for Cardioprotection in Ischemic Heart Disease. Internal Medicine, 1999, 38, 305-306.	0.7	6

#	Article	IF	Citations
127	The effects of nucleotides and potassium channel openers on the SUR2A/Kir6.2 complex K + channel expressed in a mammalian cell line, HEK293T cells. Pflugers Archiv European Journal of Physiology, 1998, 435, 595-603.	2.8	74
128	Inhibition of Angiotensin-converting Enzyme Increases the Nitric Oxide Levels in Canine Ischemic Myocardium. Journal of Molecular and Cellular Cardiology, 1998, 30, 2461-2466.	1.9	24
129	Increased Expression of P-Selectin on Platelets Is a Risk Factor for Silent Cerebral Infarction in Patients With Atrial Fibrillation. Circulation, 1998, 98, 1721-1727.	1.6	124
130	Bradykinin Mediation of Ca 2+ -Activated K + Channels Regulates Coronary Blood Flow in Ischemic Myocardium. Circulation, 1997, 95, 1560-1567.	1.6	41
131	Role of nitric oxide in regulation of coronary blood flow during myocardial ischemia in dogs. Journal of the American College of Cardiology, 1996, 27, 1804-1812.	2.8	47
132	Increased Release of NO During Ischemia Reduces Myocardial Contractility and Improves Metabolic Dysfunction. Circulation, 1996, 93, 356-364.	1.6	65
133	Role of Activation of Protein Kinase C in the Infarct SizeLimiting Effect of Ischemic Preconditioning Through Activation of Ecto-5â€²-nucleotidase. Circulation, 1996, 93, 781-791.	1.6	100
134	Î± 1 -Adrenoceptor Activation Increases Ecto-5â€²-Nucleotidase Activity and Adenosine Release in Rat Cardiomyocytes by Activating Protein Kinase C. Circulation, 1995, 91, 2226-2234.	1.6	83
135	Beneficial Effects of Inhibition of Angiotensin-Converting Enzyme on Ischemic Myocardium During Coronary Hypoperfusion in Dogs. Circulation, 1995, 92, 950-961.	1.6	83
136	An increase in afterload augments ventricular relaxation rate in isolated perfused canine hearts. Cardiovascular Research, 1985, 19, 649-654.	3.8	10